Skip to main content
Log in

Substance Misuse in Patients with Schizophrenia

Epidemiology and Management

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Substance misuse in individuals with schizophrenia is very common, especially in young men, in communities where use is frequent and in people receiving inpatient treatment. Problematic use occurs at very low intake levels, so that most affected people are not physically dependent (with the exception of nicotine). People with schizophrenia and substance misuse have poorer symptomatic and functional outcomes than those with schizophrenia alone. Unless there is routine screening, substance misuse is often missed in assessments. Service systems tend to be separated, with poor inter-communication, and affected patients are often excluded from services because of their comorbidity. However, effective management of these disorders requires a fully integrated approach because of the close inter-relationship of the disorders. Use of atypical antipsychotics may be especially important in this population because of growing evidence (especially on clozapine and risperidone) that nicotine smoking, alcohol misuse and possibly some other substance misuse is reduced. Several pharmacotherapies for substance misuse can be used safely in people with schizophrenia, but the evidence base is small and guidelines for their use are necessarily derived from experience in the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Mercier C, Renaud C, King S. A thirty-year retrospective study of hospitalization among severely mentally ill patients. Can J Psychiatry 1994; 39(2): 95–102

    PubMed  CAS  Google Scholar 

  2. Australian Institute of Health andWelfare. 1998 National drug strategy household survey: first results. Canberra: Australian Institute of Health and Welfare, 1999

    Google Scholar 

  3. Regier D, Farmer M, Rae D, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19): 2511–8

    Article  PubMed  CAS  Google Scholar 

  4. Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry 2000; 34(2): 221–36

    Article  PubMed  CAS  Google Scholar 

  5. Kavanagh DJ, McGrath JJ, Jenner L. Substance use in psychotic disorders: Results from the Australian survey of mental health and wellbeing [abstract]. Acta Psychiatr Scand 2000; 102 Suppl. 404: 5

    Google Scholar 

  6. Patkar AA, Alexander RC, Lundy A, et al. Changing patterns of illicit substance use among schizophrenic patients: 1984–1996. Am J Addict 1999; 8(1): 65–71

    Article  PubMed  CAS  Google Scholar 

  7. Hall W, Ross J, Lynskey M, et al. How many dependent heroin users are there in Australia? Med J Aust 2000; 173(10): 528–31

    PubMed  CAS  Google Scholar 

  8. Maxwell JC. Changes in drug use in Australia and the United States: Results from the 1995 and 1998 National Household Surveys. Drug Alcohol Rev 2001; 20(1): 37–48

    Article  Google Scholar 

  9. Saunders JB, Richards A. Getting to grips with heroin and other opioid use. Med J Aust 2000; 173(10): 509–10

    PubMed  CAS  Google Scholar 

  10. Mueser KT, Yarnold PR, Rosenberg SD, et al. Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates, and subgroups. Schizophr Bull 2000; 26(1): 179–92

    Article  PubMed  CAS  Google Scholar 

  11. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 2001; 48(1): 109–23

    Article  PubMed  CAS  Google Scholar 

  12. Mueser K, Yarnold P, Levinson D, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 1990; 16(1): 31–55

    Article  PubMed  CAS  Google Scholar 

  13. Kavanagh DJ, Saunders JB, Young R, et al. Evaluation and brief intervention for substance abuse in early psychosis: A report to AUSEINET. Brisbane: Department of Psychiatry, University of Queensland; 1999

    Google Scholar 

  14. Condren RM, O’Connor J, Browne R. Prevalence and patterns of substance misuse in schizophrenia: A catchment area casecontrol study. Psychiatr Bull 2001; 25(1): 17–20

    Article  Google Scholar 

  15. Dickey B, Azeni H, Weiss R, et al. Schizoprhenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ 2000; 3(1): 27–33

    Article  PubMed  Google Scholar 

  16. Brunette M, Drake R. Gender differences in patients with schizophrenia and substance abuse. Compr Psychiatry 1997; 38(2): 109–16

    Article  PubMed  CAS  Google Scholar 

  17. Hoffer A, Foster HD. Why schizophrenics smoke but have a lower incidence of lung cancer: Implications for the treatment of both disorders. J Orthomol Med 2000; 15: 141–4

    Google Scholar 

  18. Lichtermann D, Ekelund J, Pokkala E, et al. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001; 58: 573–8

    Article  PubMed  CAS  Google Scholar 

  19. Gearon JS, Bellack AS. Sex differences in illness presentation, course and level of functioning in substance-abusing schizoprhenia patients. Schizophr Res 2000; 43(1): 65–70

    Article  PubMed  CAS  Google Scholar 

  20. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and susbtance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47(8): 853–8

    PubMed  CAS  Google Scholar 

  21. Goff D, Henderson D, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149(9): 1189–94

    PubMed  CAS  Google Scholar 

  22. Ziedonis D, Kosten T, Glazer W, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994; 45: 204–6

    PubMed  CAS  Google Scholar 

  23. Zaretsky A, Rector N, Seeman M, et al. Current cannabis use and tardive dyskinesia. Schizophr Res 1993; 11: 3–8

    Article  PubMed  CAS  Google Scholar 

  24. Dixon L, Weiden P, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33: 121–2

    Article  PubMed  CAS  Google Scholar 

  25. Raesaenen P, Tiihonen J, Isohanni M, et al. Schizophrenia, alcohol abuse, and violent behavior: A 26-year follow-up study of an unselected birth cohort. Schizophr Bull 1998; 24(3): 437–41

    Article  Google Scholar 

  26. Drake R, Osher F, Wallach M. Alcohol use and abuse in schizophrenia: A prospective community study. J Nerv Ment Dis 1989; 177: 408–14

    Article  PubMed  CAS  Google Scholar 

  27. Krystal JH, D’Souza DC, Madonick S, et al. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999; 35 Suppl. 6: S35–49

    Article  PubMed  Google Scholar 

  28. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150(12): 1856–61

    PubMed  CAS  Google Scholar 

  29. Kumari V, Toone B, Gray JA. Habituation and prepulse inhibition of the acoustic startle reflex: Effects of smoking status and psychosis-proneness. Pers Indiv Diff 1997; 23(2): 183–91

    Article  Google Scholar 

  30. Levin ED, Wilson W, Rose JE, et al. Nicotine-haloperidol interactions and cognitive performance in schizophrenia. Neuropsychopharmacology 1996; 15(5): 429–36

    Article  PubMed  CAS  Google Scholar 

  31. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148(2): 224–30

    PubMed  CAS  Google Scholar 

  32. Trumbetta SL, Mueser KT, Quimby E, et al. Social netowrks and clinical outcomes of dually diagnosed homeless persons. Behav Ther 1999; 30: 407–30

    Article  Google Scholar 

  33. Bellack AS, DiClimente CC. Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999; 50(1): 75–80

    PubMed  CAS  Google Scholar 

  34. Sobell LC, Sobell MB. Alcohol timeline followback users’ manual. Toronto: Addiction Research Foundation, 1995

    Google Scholar 

  35. Appleby L, Dyson V, Luchins D, et al. The impact of substance use screening on a public psychiatric inpatient population. Psychiatr Serv 1997; 48: 1311–6

    PubMed  CAS  Google Scholar 

  36. Carey K, Correia C, Cocco K. Reliability and validity of the addiction severity index among outpatients with severe mental illness. Psychol Assess 1997; 9(4): 422–8

    Article  Google Scholar 

  37. Seinen A, Dawe S, Kavanagh DJ, et al. An examination of the utility of the AUDIT in people diagnosed with schizophrenia. J Stud Alcohol 2000; 61: 744–50

    PubMed  Google Scholar 

  38. Rosenberg SD, Drake RE, Wolfoprd GL, et al. Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental ilness. Am J Psychiatry 1998; 155(2): 232–8

    PubMed  CAS  Google Scholar 

  39. Zevin S, Jacob-Ill P, Geppetti P, et al. Clinical pharmacology of oral cotinine. Drug Alcohol Depend 2000; 60(1): 13–8

    PubMed  CAS  Google Scholar 

  40. McPhillips MA, Kelly FJ, Barnes TR, et al. Detecting comorbid substance misuse among people with schizophrenia in the community: a study comparing the results of questionnaires with analysis of hair and urine. Schizophr Res 1997; 25(2): 141–8

    Article  PubMed  CAS  Google Scholar 

  41. Waage H, Sisland T, Urdal P, et al. Discrimination of smoking status by thiocyanate and cotinine in serum, and carbon monoxide in expired air. Int J Epidemiol 1992; 21(3): 488–93

    Article  PubMed  CAS  Google Scholar 

  42. Aguinis H, Pierce CA, Quigley BM. Enhancing the validity of self-reported alcohol and marijuana consumption using a bogus pipeline procedure: A meta-analytic review. Basic Appl Soc Psychol 1995; 16(4): 515–27

    Article  Google Scholar 

  43. Carey KB, Simons J. Utility of collateral information in assessing substance use among psychiatric outpatients. J Subst Abuse 2000; 11(2): 139–47

    Article  PubMed  CAS  Google Scholar 

  44. Rankin H. Validity of self-reports in clinical settings. Behav Assess 1990; 12(1): 107–16

    Google Scholar 

  45. Schuckit M. Drug and Alcohol Abuse. A Clinical Guide to Diagnosis and Treatment. New York: Kluwer Academic/Plenum, 2000

    Google Scholar 

  46. Drake R, Wallach M. Moderate drinking among people with severe mental illness. Hosp Community Psychiatry 1993; 44(8): 780–5

    PubMed  CAS  Google Scholar 

  47. Cinciripini PM, Lapitsky L, Seay S, et al. The effects of smoking schedules on cessation outcome: Can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol 1995; 63(3): 388–99

    Article  PubMed  CAS  Google Scholar 

  48. US Department of Health and Human Services. National trends in smoking cessation, in the health benefits of smoking cessation: a report of the Surgeon General. Washington: US Govt Printing Office, 1994

    Google Scholar 

  49. Miller W, Rollnick S. Motivational interviewing: preparing people to change addictive behaviour. New York: Guilford, 1991

    Google Scholar 

  50. Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Dis 1999; 187(10): 630–5

    Article  PubMed  CAS  Google Scholar 

  51. Drake R, Mercer-McFadden C, Mueser K, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998; 24(4): 589–608

    Article  PubMed  CAS  Google Scholar 

  52. Kavanagh DJ, White A, Young R, et al. Towards an Integrated and Sensitive Family Intervention for Comorbid Substance Abuse and Schizophrenia: A Comment on Sheils and Rolfe (2000). Aust J Fam Ther 2000; 21: 88–90

    Google Scholar 

  53. Graham H. The role of dysfunctional beliefs in individuals who experience psychosis and use substances: implications for cognitive therapy and medication adherence. Behav Cog Psychother 1998; 26: 193–208

    Google Scholar 

  54. Hunt GM, Azrin NH. A community-reinforcement approach to alcoholism. Behav Res Ther 1973; 11(1): 91–104

    Article  PubMed  CAS  Google Scholar 

  55. Drake RE, McHugo GJ, Clark RE, et al. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: A clinical trial. Am J Orthopsychiatry 1998; 68(2): 201–15

    Article  PubMed  CAS  Google Scholar 

  56. Kavanagh D. An intervention for substance abuse in Schizophrenia. Behav Change 1995; 12(1): 20–30

    Google Scholar 

  57. Kavanagh DJ, Young R, Boyce L, et al. Substance abuse treatment options for schizophrenia (STOP): a new intervention for dual diagnosis. J Ment Health 1998; 7(2): 135–43

    Article  Google Scholar 

  58. Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. J Clin Psychiatry 2000; 61 Suppl. 14: 27–32

    PubMed  CAS  Google Scholar 

  59. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35(1): 51–68

    Article  PubMed  CAS  Google Scholar 

  60. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and metaanalysis of randomized trials. Am J Psychiatry 1999; 156(7): 990–9

    PubMed  CAS  Google Scholar 

  61. Emsley RA. Role of neweer atypical antipsychotics in the management of treatment-resistant schizophrenia. CNS Drugs 2000; 13(6): 409–20

    Article  CAS  Google Scholar 

  62. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999; 35: S61–6

    Article  PubMed  Google Scholar 

  63. Voruganti LNP, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185(7): 463–5

    Article  PubMed  CAS  Google Scholar 

  64. Rosenheck R, Dunn L, Peszke M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999; 156(1): 88–93

    PubMed  CAS  Google Scholar 

  65. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154(4): 466–74

    PubMed  CAS  Google Scholar 

  66. Green MF, Marshall BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154: 799–804

    PubMed  CAS  Google Scholar 

  67. Hagger C, Bucley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702–12

    Article  PubMed  CAS  Google Scholar 

  68. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine [letter]. Am J Psychiatry 1995; 152: 959

    PubMed  CAS  Google Scholar 

  69. George TP, Zeidonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 1835–42

    Article  PubMed  CAS  Google Scholar 

  70. Buckley P, Thompson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994; 151(3): 385–9

    PubMed  CAS  Google Scholar 

  71. McGrath J, Emmerson WB. Fortnightly review. Treatment of schizophrenia. BMJ 1999; 319(7216): 1045–8

    Article  PubMed  CAS  Google Scholar 

  72. Currier G. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000; 61 Suppl. 14: 21–6

    PubMed  CAS  Google Scholar 

  73. Degner D, Bleich S, Grohmann R, et al. Myocarditis associated with clozapine treatment [letter]. Aust N Z J Psychiatry 2000; 34(5): 880

    Article  PubMed  CAS  Google Scholar 

  74. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 46: 125–9

    Article  PubMed  CAS  Google Scholar 

  75. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26(2): 441–9

    Article  PubMed  CAS  Google Scholar 

  76. Zimmet SV, Strous RD, Burgess ES, et al. Effect of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective study. J Clin Psychopharmacol 2000; 20(1): 94–8

    Article  PubMed  CAS  Google Scholar 

  77. Addington J. Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv 1998; 49(7): 925–8

    PubMed  CAS  Google Scholar 

  78. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992; 8: 93–102

    Article  PubMed  CAS  Google Scholar 

  79. Scurlock H, Lucas P. Another case of nicotine psychosis? Addiction 1996; 91(9): 1388

    Article  PubMed  CAS  Google Scholar 

  80. Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999; 21(2): 195–202

    Article  PubMed  CAS  Google Scholar 

  81. Smith CM, Pristach CA, Cartagena M. Obligatory cessation of smoking by psychiatric inpatients. Psychiatr Serv 1999; 50(1): 91–4

    PubMed  CAS  Google Scholar 

  82. Evins AE, Tisdale T. Bupropion and Smoking Cessation. Am J Psychiatry 1999; 156(5): 798–9

    PubMed  CAS  Google Scholar 

  83. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustainedrelease bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001; 158(4): 635–7

    Article  PubMed  CAS  Google Scholar 

  84. Howard WT, Warnock JK. Howard WT, et al. Bupropion-Induced Psychosis [letter]. Am J Psychiatry 1999; 156(12): 2017–8

    PubMed  CAS  Google Scholar 

  85. Golden RN, James SP, Sherer MA, et al. Psychoses associated with bupropion treatment. Am J Psychiatry 1985; 142(12): 1459–62

    PubMed  CAS  Google Scholar 

  86. Steele C. Zyban: an effective treatment for nicotine addiction. Hosp Med 2000; 61: 785–8

    PubMed  CAS  Google Scholar 

  87. Breckenridge A. Zyban: modified dosage and safety precautions. Message from Professor A. Breckenridge, Chairman, Committee on Safety of Medicines, Medicines Control Agency. Available from URL: http://www.mca.gov.uk (safety messages) [Accessed 2001 May 31]

  88. Sernyak MJ, Glazer WM, Heninger GR, et al. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 1998; 18: 248–51

    Article  PubMed  CAS  Google Scholar 

  89. Hughes J, Cook C. The efficacy of disulfiram: A review of outcome studies. Addiction 1997; 92(4): 381–95

    Article  PubMed  CAS  Google Scholar 

  90. Brenner LM, Karper LP, Krystal JH. Short-term use of disulfiram with clozapine. J Clin Psychopharmacol 1994; 14: 213–5

    Article  PubMed  CAS  Google Scholar 

  91. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. In press

  92. Wetzler S, Sanderson WC. Treatment Strategies for Patients with Psychiatric Comorbidity. New York: John Wiley and Sons, 1997

    Google Scholar 

  93. Poulsen E, Loft S, Anderson JR, et al. Disulfiram therapy-adverse drug reactions and interactions. Acta Psychiatr Scand 1992; 86: 59–66

    Article  Google Scholar 

  94. Perry PJ, Alexander B, Liskow BI. Psychotropic drug handbook. 7th ed. Washington (DC): American Psychiatric Press, Inc., 1997

    Google Scholar 

  95. Larson EW, Olincy A, Rummans TA, et al. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: A review. Alcohol Clin Exper Res 1992; 16(1): 125–30

    Article  CAS  Google Scholar 

  96. McKenna GJ. Methadone and Opiate Drugs: Psychotropic Effect and Self-Medication. Ann N Y Acad Sci 1982; 398: 44–53

    Article  PubMed  CAS  Google Scholar 

  97. Vereby K, Volavka J, Clouet D. Endorphines in psychiatry: An overview and a hypothesis. Archives Gen Psychiatry 1978; 35: 877–88

    Article  Google Scholar 

  98. Levinson I, Galynker II, Rosenthal RN. Methadone withdrawal psychosis. J Clin Psychiatry 1995; 56(2): 73–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David J. Kavanagh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kavanagh, D.J., McGrath, J., Saunders, J.B. et al. Substance Misuse in Patients with Schizophrenia. Drugs 62, 743–755 (2002). https://doi.org/10.2165/00003495-200262050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262050-00003

Keywords

Navigation